Clinical Trial Update: Volrustomig Priming Regimens Exploratory Phase II Platform Study [Phase 2]

View source ↗

Summary

AstraZeneca's exploratory Phase II platform trial is evaluating Volrustomig priming regimens in non-small cell lung cancer, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Volrustomig

Snippet

Sponsor: AstraZeneca | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: RECRUITING